Results 221 to 230 of about 15,546 (262)
Genetic Confirmation of Clonal Spread of <i>Candida auris</i> from Southern to Northern Nevada. [PDF]
J Fungi (Basel)Resong PJ +5 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Drugs, 2004
Micafungin, an echinocandin antifungal agent with a novel mechanism of action, inhibits beta-(1,3)-D-glucan synthase interfering with fungal cell wall synthesis. It shows excellent antifungal activity against a broad range of Candida spp., including azole-resistant strains, and Aspergillus spp. in in vitro and animal studies.
Blair Jarvis +2 more
+11 more sources
Micafungin, an echinocandin antifungal agent with a novel mechanism of action, inhibits beta-(1,3)-D-glucan synthase interfering with fungal cell wall synthesis. It shows excellent antifungal activity against a broad range of Candida spp., including azole-resistant strains, and Aspergillus spp. in in vitro and animal studies.
Blair Jarvis +2 more
+11 more sources
Clinical Pharmacokinetics and Pharmacodynamics of Micafungin [PDF]
Clinical Pharmacokinetics, 2017 Micafungin is a selective inhibitor of the synthesis of fungal 1,3-β-D-glucan, an essential component of the fungal cell wall. It is available as a powder for infusion only and is registered for the treatment of invasive and esophageal candidiasis in addition to prophylaxis of Candida infections in both adults and children.
Roeland E Wasmann +2 more
exaly +6 more sources
Micafungin: A New Echinocandin [PDF]
Clinical Infectious Diseases, 2006 Micafungin, a potent inhibitor of 1,3-beta-D-glucan synthase, has become the second available agent in the echinocandins class that is approved for use in clinical practice. This agent shares with caspofungin an identical spectrum of in vitro activity against Candida albicans, non-albicans species of Candida, and Aspergillus species, as well as several
Jack D. Sobel +1 more
exaly +4 more sources
Breakthrough Invasive Candidiasis in Patients on Micafungin [PDF]
Journal of Clinical Microbiology, 2010 ABSTRACT For Candida species, a bimodal wild-type MIC distribution for echinocandins exists, but resistance to echinocandins is rare. We characterized isolates from patients with invasive candidiasis (IC) breaking through ≥3 doses of micafungin therapy during the first 28 months of its use at our center ...
Guillermo Garcia-Effron
exaly +5 more sources
Micafungin: the US perspective
Expert Review of Anti-infective Therapy, 2005Invasive fungal infections cause considerable morbidity and mortality in nosocomial settings and amongst immunocompromised hosts. Invasive candidiasis and aspergillosis remain the most common invasive fungal infections, with Candida spp. constituting the fourth most common bloodstream infection in the USA.
Aimee K. Zaas, William J. Steinbach
openaire +3 more sources
Micafungin: a therapeutic review
Expert Review of Anti-infective Therapy, 2004In recent decades, the incidence of aspergillosis, candidiasis and clinically important deep mycoses has been increasing, with advances in transplantation medicine and anticancer chemotherapy. Micafungin (FK463, Fujisawa Healthcare) has been developed as a novel type of antifungal agent, which inhibits 1,3-beta-D-glucan synthase in the fungal cell wall.
Yasuhito Higashiyama, Shigeru Kohno
openaire +3 more sources